Remdesivir and Mortality in Patients with COVID-19

8/19 Late treatment study

Diaz et al., Clinical Infectious Diseases, doi:10.1093/cid/ciab698 (Peer Reviewed)
Remdesivir and Mortality in Patients with COVID-19

Source PDF Share Tweet

Retrospective 1138 hospitalized patients in the USA, 286 treated with remdesivir, showing lower mortality with treatment.

Diaz et al., 8/19/2021, retrospective, USA, North America, peer-reviewed, 45 authors.

risk of death, 34.7% lower, RR 0.65, p = 0.01, treatment 33 of 286 (11.5%), control 173 of 852 (20.3%), adjusted per study, odds ratio converted to relative risk, multivariable Cox proportional-hazards.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 29 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit